HER2, TOP2A, and TIMP-1 and responsiveness to adjuvant anthracycline-containing chemotherapy in high-risk breast cancer patients. - Wikidata - awgldk - TriplyDB

HER2, TOP2A, and TIMP-1 and responsiveness to adjuvant anthracycline-containing chemotherapy in high-risk breast cancer patients.

HER2, TOP2A, and TIMP-1 and responsiveness to adjuvant anthracycline-containing chemotherapy in high-risk breast cancer patients.

http://www.wikidata.org/entity/Q38418568

about

Cancer Hallmarks, Biomarkers and Breast Cancer Molecular Subtypes TIMP-1 and responsiveness to gemcitabine in advanced breast cancer; results from a randomized phase III trial from the Danish breast cancer cooperative group.Mechanisms regulating resistance to inhibitors of topoisomerase II.Chromosome 17 centromere duplication and responsiveness to anthracycline-based neoadjuvant chemotherapy in breast cancer.Positive response to neoadjuvant cyclophosphamide and doxorubicin in topoisomerase II nonamplified/HER2/neu negative/polysomy 17 absent breast cancer patients TOP2Ahigh is the phenotype of recurrence and metastasis whereas TOP2Aneg cells represent cancer stem cells in prostate cancer.Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy.Quantification and clinical relevance of gene amplification at chromosome 17q12-q21 in human epidermal growth factor receptor 2-amplified breast cancers.Prospective evaluation of serum tissue inhibitor of metalloproteinase 1 and carbonic anhydrase IX in correlation to circulating tumor cells in patients with metastatic breast cancer.HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy.A phase II study of Epirubicin in oxaliplatin-resistant patients with metastatic colorectal cancer and TOP2A gene amplification.Prognostic significance of tissue inhibitor of metalloproteinase-1 in breast cancer.Biomarkers characterization of circulating tumour cells in breast cancer patients Systematic assessment of multi-gene predictors of pan-cancer cell line sensitivity to drugs exploiting gene expression data.Alterations of biomarker profiles after neoadjuvant chemotherapy in breast cancer: tumor heterogeneity should be taken into consideration.Is TIMP-1 immunoreactivity alone or in combination with other markers a predictor of benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial?Biomarker-guided repurposing of chemotherapeutic drugs for cancer therapy: a novel strategy in drug development.Emerging biomarkers in breast cancer care.Clinical utility of level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1.Tissue inhibitor of metalloproteinase 1 (TIMP-1) as a biomarker in gastric cancer: a review.The role of anthracyclines in the treatment of early breast cancer.TIMP-1 in combination with HER2 and TOP2A for prediction of benefit from adjuvant anthracyclines in high-risk breast cancer patients.Integrated diagnostic network construction reveals a 4-gene panel and 5 cancer hallmarks driving breast cancer heterogeneity.TIMPs: versatile extracellular regulators in cancer.TIMP-1 overexpression does not affect sensitivity to HER2-targeting drugs in the HER2-gene-amplified SK-BR-3 human breast cancer cell line.TOP2A protein by quantitative immunofluorescence as a predictor of response to epirubicin in the neoadjuvant treatment of breast cancer.Evaluation of chromosome 17 polysomy in breast cancer by FISH analysis of whole nuclei, and its clinicopathological significance.Tumor tissue levels of Tissue Inhibitor of Metalloproteinases-1 (TIMP-1) and outcome following adjuvant chemotherapy in premenopausal lymph node-positive breast cancer patients: A retrospective study.The levels of Ki-67 positive are positively associated with lymph node metastasis in invasive ductal breast cancer.Forty years of landmark trials undertaken by the Danish Breast Cancer Cooperative Group (DBCG) nationwide or in international collaboration.Overexpression of TIMP-1 and Sensitivity to Topoisomerase Inhibitors in Glioblastoma Cell Lines.Co-expression of TIMP-1 and its cell surface binding partner CD63 in glioblastomas.Predictive role of HER2/neu, topoisomerase-II-alpha, and tissue inhibitor of metalloproteinases (TIMP-1) for response to adjuvant taxane-based chemotherapy in patients with intermediate-risk breast cancer: results from the WSG-AGO EC-Doc trial.

P2860

Q26743510-D4C02F3D-8777-4510-8221-B7758EE68252 Q33880656-ABAC1AD6-7EF1-4245-8D24-0FA312C148BA Q34361770-C3860393-59B1-49AA-A043-D3D8E4CBCC99 Q34417532-4EED7988-B6A5-4BE3-8A2B-84AF32044EE3 Q34417986-27B0E478-B532-4897-9DA7-E5937638AF7D Q34619422-49824C83-7E51-4DDC-8900-4FCAD66E379F Q34743488-21967495-2907-474B-A3FA-7952666726D8 Q35029573-62FE3034-FECD-4BF6-B04A-ED3FE6FB707D Q35608684-504E6187-5C1D-49EA-A602-D264B25847CD Q35744973-157C51D7-1CBB-47BD-A6EA-5FC3CEE2545F Q35921206-F862547C-0877-4C77-B6EF-7F1DC765901A Q36231009-A71CED20-E2A5-4F96-9B69-5B5A15819FB6 Q36245346-0BE270BE-C3DF-484B-967A-11F2D13C92BD Q36309864-F1F0E354-257E-47D9-A844-0C6D325E94FF Q36546821-5AB619AE-50C5-47DE-B9AE-EB8D3276BF1C Q36903127-3684E11A-9ED1-4612-B9F5-E2B0EE3466E0 Q37413146-CA773157-F567-4BBB-A21C-E6881A400B36 Q37779305-66C158F8-870A-4C45-891F-9D1DFA59F4CB Q37809871-21493A07-2393-4AA0-9219-453C8A30DD23 Q38119975-47FA9FEF-4A5E-43F3-8A2D-93410CACF069 Q38207452-DF51CD48-AEF7-48A7-8B65-63212BF87089 Q38406512-D7632987-A76B-4541-9DBE-DCC163A14EEE Q38430594-01E3D33B-8A30-4F4B-AC60-A345E72CF2B6 Q38785433-B63338F4-2E75-4116-9353-22CE32C29A03 Q39207632-BA2138DA-DDD8-47D7-9E0F-0284765459C8 Q39336778-2DA46BBC-3247-4ADB-86A0-E3C73B35161C Q40450070-2F3ADCA0-5BA9-41DB-ADBB-7C1B60CDC849 Q42573382-F5A9F46F-C981-4C5D-BF8F-49D0A1E17108 Q46324717-EA24208E-6B2D-48E2-929C-F535B5852C83 Q47368780-9A923933-BCB5-43CE-8523-58457C1CB360 Q47722570-0D6D3B84-7C0C-4429-B2C0-1D3033482D6F Q55059317-A064A732-A554-4CA7-96A7-C082275F6058 Q55066764-3B1CBB27-6729-40C1-B881-8F0D51903EB8

P2860

HER2, TOP2A, and TIMP-1 and responsiveness to adjuvant anthracycline-containing chemotherapy in high-risk breast cancer patients.

http://www.wikidata.org/entity/Q38418568

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

2009年论文

@zh

2009年论文

@zh-cn

name

HER2, TOP2A, and TIMP-1 and re ...... h-risk breast cancer patients.

@en

type

label

HER2, TOP2A, and TIMP-1 and re ...... h-risk breast cancer patients.

@en

prefLabel

HER2, TOP2A, and TIMP-1 and re ...... h-risk breast cancer patients.

@en

P1433

Q38418568-AD5D6FD4-368E-4035-BBDA-12E75DCED542

P1476

Q38418568-63681A6F-8261-4053-89A1-224252C0573D

P2093

Q38418568-06967BCF-FCA9-4E29-A98D-C6865EAF932F

Q38418568-17271A1D-D93D-4C1C-9120-44A85317A2FD

Q38418568-1FCA05D8-B14B-4744-AF49-0E6CA913326D

Q38418568-22C583EC-0917-4595-B7FC-285D898690B6

Q38418568-26D506CF-FF06-400C-8A64-EFE1DCA5FA87

Q38418568-2CDA4578-5EFD-4732-9490-D9EAC70AB467

Q38418568-B3079499-C6E9-4766-9150-D7F3C42A0506

Q38418568-C0AA9E3F-A495-46DF-B887-77F1E446EAEF

Q38418568-EF334178-C0AA-499C-876F-67CA89ED8963

P304

Q38418568-DFD5F449-91A8-459A-8186-F0E57D008CCC

P31

Q38418568-1F90DFD8-8E38-44E9-BD79-808746D2E37D

P356

Q38418568-9647CD35-7715-462B-B815-D5C680B7A68E

P407

Q38418568-FEE45316-8011-40C0-9815-4A3179974168

P433

Q38418568-217F2B05-4CBF-4F01-83CC-3F4F36A0F53A

P478

Q38418568-33C9BF10-FF50-4546-829C-6ECE4E152C88

P50

Q38418568-A02270E8-208E-4958-AD5B-AB9AE592DCEC

P577

Q38418568-4B532320-768E-42B3-A19C-C838209049A0

P698

Q38418568-3F292F66-B818-4ED5-A03C-E7EA16921B19

P921

Q38418568-14FB149C-E7B5-4691-A4A4-8E0BF5F79C5D

P356

JCO.2009.24.1166

P1433

Journal of Clinical Oncology

P1476

HER2, TOP2A, and TIMP-1 and re ...... h-risk breast cancer patients.

@en

P2093

Ann S Knoop

http://www.w3.org/2001/XMLSchema#string

Birgitte B Rasmussen

http://www.w3.org/2001/XMLSchema#string

Eva Balslev

http://www.w3.org/2001/XMLSchema#string

Gro L Willemoe

http://www.w3.org/2001/XMLSchema#string

Henning T Mouridsen

http://www.w3.org/2001/XMLSchema#string

Kirsten V Nielsen

http://www.w3.org/2001/XMLSchema#string

Maj-Britt Jensen

http://www.w3.org/2001/XMLSchema#string

Nils Brünner

http://www.w3.org/2001/XMLSchema#string

Pernille B Hertel

http://www.w3.org/2001/XMLSchema#string

P304

984-990

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2009.24.1166

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-12-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20038724

http://www.w3.org/2001/XMLSchema#string

P921